Myconostica, a UK-based medical diagnostic company which specialises in rapid and highly specific tests for life-threatening fungal infections, announced the launch of a new test to assist medical and scientific professionals identify the two most common causes of fungal pneumonia.
The assay, FXGTM: RESP (Asp +), uses Real-Time PCR technology to accurately and rapidly identify infections caused by both Aspergillus and Pneumocystis.
- Fungal pneumonia is the leading cause of infectious death in leukaemia and bone marrow transplant patients and is the most common first manifestation of AIDS.
- FXGTM: RESP (Asp +) can identify Aspergillus and Pneumocystis within 4 hours, which account for over 95% of cases of fungal pneumonia.
- Diagnosis followed by antifungal treatment within the first 10 days of infection reduces the mortality rate from 90% to 40%.
FXGTM: RESP (Asp +) is a sensitive and specific assay designed to aid healthcare professionals involved in the diagnosis and treatment of fungal pneumonia. Traditional methods used to identify fungal pneumonia infections are well-documented as being inaccurate, insensitive and slow, with a result typically taking 2 to 3 days. Combining Real-Time PCR technology with Myconostica's fungal DNA extraction system, MycXtraTM, FXGTM: RESP (Asp +) provides a rapid, sensitive and specific alternative to the traditional techniques used to identify Aspergillus and Pneumocystis infection.
FXGTM: RESP (Asp +) is the first in a pipeline of products from Myconostica designed to assist in the diagnosis of fungal disease. Further tests in the FXGTM series will also target critical fungal infections, such as Candida, which cause sepsis and bloodstream infections.